Detalles de la búsqueda
1.
Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy.
Clin Exp Allergy
; 54(4): 241-252, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38332535
2.
Biomarkers in atopic dermatitis.
J Allergy Clin Immunol
; 151(5): 1163-1168, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36792449
3.
Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis.
Allergy
; 78(8): 2266-2276, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36934403
4.
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Br J Dermatol
; 189(3): 327-335, 2023 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37177895
5.
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Acta Derm Venereol
; 103: adv00872, 2023 Feb 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36794894
6.
Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters.
J Allergy Clin Immunol
; 149(1): 125-134, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34237306
7.
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
Allergy
; 77(11): 3398-3407, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35837880
8.
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
Pediatr Allergy Immunol
; 33(12): e13887, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564878
9.
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
Acta Derm Venereol
; 102: adv00666, 2022 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35098318
10.
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Acta Derm Venereol
; 102: adv00820, 2022 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36420885
11.
Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers.
J Allergy Clin Immunol
; 147(1): 189-198, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32526312
12.
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
J Am Acad Dermatol
; 84(4): 1000-1009, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32946967
13.
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
Acta Derm Venereol
; 101(10): adv00573, 2021 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34396421
14.
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Allergy
; 75(1): 116-126, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31593343
15.
Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation.
Clin Exp Allergy
; 54(4): 294-296, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38158774
16.
Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
Clin Exp Allergy
; 53(2): 239-243, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36550628
17.
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies.
Clin Exp Allergy
; 53(5): 582-585, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36779570
18.
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series.
Clin Exp Allergy
; 53(5): 586-589, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36924265
19.
IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval.
Clin Exp Allergy
; 53(11): 1222-1225, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37700483
20.
Limited excretion of dupilumab into breastmilk: A case report.
J Eur Acad Dermatol Venereol
; 37(9): e1154-e1155, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37143362